Skip to Main Content

Author Details

Wolfgang E Berdel
University Hospital Munster
1976
645
82
PMIDPaper TitleJournal TitlePublished Year
37883727Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.J Clin Oncol2024
37967385Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears.Blood Adv2024
38017103Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).Leukemia2024
36149944Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML.Blood Adv2023
37756525Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.Blood2023
37833543Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.Leukemia2023
37679502Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.Leukemia2023
35708137Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.Haematologica2023
37391502CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.Cancer Gene Ther2023
37087168Decentralised elements in clinical trials: recommendations from the European Medicines Regulatory Network.Lancet2023
37455345Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.Br J Haematol2023
37041198Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Leukemia2023
37236968UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.Blood Cancer J2023
37198246Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles.Commun Med (Lond)2023
36695874Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.Ann Hematol2023
36749402Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.Ann Hematol2023
36693840Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.Blood Cancer J2023
36399194A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.Ann Hematol2023
36757706Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.JAMA Oncol2023
34320176CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.Blood2022
35468621Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.Blood Adv2022
35562747Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.J Hematol Oncol2022
36457063Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.J Hematol Oncol2022
36271776Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis.Cancer2022
36064577Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.J Hematol Oncol2022
35158832Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia.Cancers (Basel)2022
35220407Targeted siRNA nanocarrier: a platform technology for cancer treatment.Oncogene2022
35267614Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe.Cancers (Basel)2022
34794176Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.Blood Adv2022
34725904Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs).Angew Chem Int Ed Engl2022
32511755Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.Br J Haematol2021
33603142Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.Leukemia2021
33901793Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.Eur J Cancer2021
33510296Author Correction: Loss-of-function uORF mutations in human malignancies.Sci Rep2021
33618424Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.Br J Haematol2021
33926021Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.Cancers (Basel)2021
33810203Unintended Regulatory Caused Early Death-A Difficult Endpoint in Cancer Patient Care and Treatment.Cancers (Basel)2021
33779471Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.Leuk Lymphoma2021
34857808Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia.Sci Rep2021
34884988Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease.Cancers (Basel)2021
35122024Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.Nat Cancer2021
34559198Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML.Blood Adv2021
34459887Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.Blood Adv2021
34535016A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia.Blood Adv2021
34477953The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.Ann Hematol2021
34200318Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.Cancers (Basel)2021
33341918Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.Ann Hematol2021
33399480Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysis.Leuk Lymphoma2021
33382105Long-Term Follow-Up on Systemic Bevacizumab Treatment in Recurrent Respiratory Papillomatosis.Laryngoscope2021
31413097<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.Haematologica2020
  • 1 - 50 of 645

Recommended Authors

Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 4
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 6
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 4
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 11
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 0
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 4
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 2
Vinay K Jain
University of Texas M.D. Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 5
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 5
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 0
Timothy M Kuzel
548377Rush University Medical Center
Career Start Year 1988
Number of shared co-authors 0
Shifra Ash
Ruth Rappaport Children's Hospital
Career Start Year 1988
Number of shared co-authors 1
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 27
David M Loeb
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 2
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 3
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 3
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 2
Jean Michon
Institut Curie
Career Start Year 1983
Number of shared co-authors 3
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Career Start Year 1982
Number of shared co-authors 19
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 0
Fabien Calvo
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 2
John F DiPersio
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 8
Peter J Selby
College of Agriculture and Life Sciences, Cornell University
Career Start Year 1977
Number of shared co-authors 0
David W Hedley
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1975
Number of shared co-authors 2
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 0
Robin Fo??
Sapienza University.
Career Start Year 1968
Number of shared co-authors 6
William A Robinson
National Centre for Asbestos Related Diseases, University of Western Australia
Career Start Year 1967
Number of shared co-authors 2

Collaborators

Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 38
Friedrich St??lzel
University Hospital TU Dresden
Co-authored papers 20
Sven Diederichs
Medical Center - University of Freiburg, University of Freiburg
Co-authored papers 19
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 17
Claudia Rossig
University Children's Hospital Muenster
Co-authored papers 16
Chunaram Choudhary
The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen
Co-authored papers 13
Hans-Ulrich Klein
Columbia University Irving Medical Center
Co-authored papers 10
Aarif M N Batcha
Institute for Medical Information Processing
Co-authored papers 7
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Co-authored papers 6
Cyrus Khandanpour
University Hospital of Muenster
Co-authored papers 5
Stefan S Bielack
Co-authored papers 5
Berno Dankbar
Co-authored papers 3
Michael Heuser
Hannover Medical School
Co-authored papers 3
Frank Rosenbauer
University Munster
Co-authored papers 3
Daniel G Tenen
Harvard Stem Cell Institute, Harvard Medical School
Co-authored papers 3
Leo Ruhnke
University Hospital Dresden
Co-authored papers 3
Frank Buchholz
University Hospital Carl Gustav Carus, Technische Universitat (TU) Dresden
Co-authored papers 3
Matthias Edinger
Regensburg University Hospital
Co-authored papers 3
Dietger Niederwieser
University of Leipzig
Co-authored papers 3
Monika Stoll
Co-authored papers 3
Miguel A Andrade-Navarro
Institute of Organismic and Molecular Evolution, Johannes Gutenberg University
Co-authored papers 2
Gudrun G??hring
Hannover Medical School
Co-authored papers 2
Marie-Jos??e H??bert
Universite de Montreal
Co-authored papers 2
Lucy A Godley
The University of Chicago
Co-authored papers 2
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Co-authored papers 2
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 2
Hermann Pavenstädt
Co-authored papers 2
Guy Sauvageau
Universite de Montreal
Co-authored papers 2
Stefan Burdach
Technische Universitat Munchen
Co-authored papers 2
Michael Detmar
Institute of Pharmaceutical Sciences, ETH Zurich
Co-authored papers 2
Release 1.2